Topics

• ANTITRUST

• Asset Management

• Data, Privacy & Cybersecurity

• Digital Health

• Employee Benefits/ERISA

• Enforcement

• False Claims Act

• FDA REGULATORY

• Health Care

• Intellectual Property

• PRIVATE EQUITY

• TAX

Capital Insights

Analysis

• Justice Department Announces New Policies Impacting Corporate Criminal Enforcement
  (March 7, 2023)
• U.S. Life Sciences Outlook 2023 (Part IV): Additional Insights on Expected Developments
  (March 1, 2023)
• Russia/Ukraine Crisis: U.S. Announces New Tranche of Sanctions and Export Controls
  (February 27, 2023)
• U.S. Life Sciences Outlook 2023 (Part III): Agency Litigation Challenges
  (February 27, 2023)
• U.S. Life Sciences Outlook 2023 (Part II): Anticipated Agency Policy Developments
  (February 23, 2023)

In The News

• Beth Weinman Presents on Considerations in Shift Toward U.S. Pharmaceutical Manufacturing
  (March 30, 2023)
• In Bloomberg Law, Margaux Hall Discusses Drugmaker Data Protection in Medicare Price Negotiation Guidance
  (March 20, 2023)
• In Bloomberg Law and Managing Intellectual Property, Scott McKeown Discusses Federal Circuit Challenge to Patent Review Rules
  (March 16, 2023)
• In Law360, Matt Rizzolo Discusses Implications in COVID-19 Vaccine IP Government Contract Case
  (March 7, 2023)
• In Managing IP, Matt Rizzolo Discusses Department of Justice Filing in Moderna Patent Case Posing Immunity Questions
  (February 23, 2023)